improve
Aspire’s founding principle was to take a medicine, a molecule or a device and enhance it.
This might be an improved presentation, a more convenient dose, or a more acceptable formulation for patients, and that principle still drives everything we do today.
Our investment in research and product development is building a product pipeline including: improved presentations, patient acceptable formulations and convenient doses, and new indications for established molecules.
Improved
presentations
In consultation with healthcare professionals and our own in-depth market research we look at how new technology can be applied to established molecules offering an alternative way of administration.
Patient acceptable
formulations & convenient doses
In these days of precision medicine and increased dose titration, we research new dosage forms which accurately reflect real world clinical requirements.
Keeping the patient at the heart of all we do, we remove potential allergens and irritants to improve their experience.
New indications for
established molecules
We’ve worked to repurpose molecules with established safety profiles for new indications alone or in combination.
We are also actively seeking collaborations to develop:
- Paediatric & Neonate formulations
- Orphan disease designation
APL1010347F2_SEP2024
